

## Accepted Manuscript

Title: Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?

Authors: Andrew Hudson, Clara Chan, David Woolf, Alan McWilliam, Crispin Hiley, James O'Connor, Neil Bayman, Fiona Blackhall, Corinne Faivre-Finn



PII: S0169-5002(18)30246-0  
DOI: <https://doi.org/10.1016/j.lungcan.2018.02.006>  
Reference: LUNG 5572

To appear in: *Lung Cancer*

Received date: 23-7-2017  
Revised date: 31-1-2018  
Accepted date: 5-2-2018

Please cite this article as: Hudson Andrew, Chan Clara, Woolf David, McWilliam Alan, Hiley Crispin, O'Connor James, Bayman Neil, Blackhall Fiona, Faivre-Finn Corinne. Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials? *Lung Cancer* <https://doi.org/10.1016/j.lungcan.2018.02.006>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?**

Andrew Hudson<sup>a,b</sup>, Clara Chan<sup>b</sup>, David Woolf<sup>b</sup>, Alan McWilliam<sup>a</sup>, Crispin Hiley<sup>c</sup>, James O'Connor<sup>a</sup>, Neil Bayman<sup>b</sup>, Fiona Blackhall<sup>a,d</sup>, Corinne Faivre-Finn<sup>a,b</sup>

<sup>a</sup> Division of Molecular and Clinical Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

<sup>b</sup> Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK

<sup>c</sup> Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, UK; Division of Cancer Studies, King's College London, London, UK

<sup>d</sup> Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK

### Highlights

- A review of concurrent chemoradiotherapy in stage 3 non-small cell lung cancer
- Recent trial data suggests a detriment to dose-escalated radiotherapy in this setting
- Large degree of heterogeneity in patient, tumour and clinical factors between cases
- Heterogeneity may be limiting the ability to detect benefits of doseescalation
- Technology advances may better stratify cases and allow safer doseescalation

### Abstract

The current standard of care for the management of inoperable stage 3 non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (cCRT) using radiotherapy dose-fractionation and chemotherapy regimens that were established 3 decades ago. In an

Download English Version:

<https://daneshyari.com/en/article/8453914>

Download Persian Version:

<https://daneshyari.com/article/8453914>

[Daneshyari.com](https://daneshyari.com)